Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections
Basic Medicine|更新时间:2026-01-09
|
Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections
Journal of Third Military Medical UniversityVol. 41, Issue 7, Pages: 678-683(2019)
作者机构:
1.409099 重庆,重庆市黔江中心医院:检验科
2.409099 重庆,重庆市黔江中心医院:输血科
作者简介:
基金信息:
the Joint Medical Research Project of Science and Technology Committee and Health and Family Planning Commission of Chongqing(2018QNXM002);the Science and Technology Committee of Qanjiang District of Chongqing(黔科计2018004)
Zuowei YUAN, Yonghong WANG, Jun HUANG, et al. Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections[J]. Journal of Third Military Medical University, 2019, 41(7): 678-683.
DOI:
Zuowei YUAN, Yonghong WANG, Jun HUANG, et al. Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections[J]. Journal of Third Military Medical University, 2019, 41(7): 678-683. DOI: 10.16016/j.1000-5404.201811017.
Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections
To develop a differential diagnostic kit for distinguishing antibodies induced by HIV-1 infection and HIV-1 vaccine and evaluate its diagnostic performance.
Methods
2
Nitrocellulose membrane was coated with HIV-1 envelope protein gp41 and HIV-1 recognition fusion peptide SK1-SK2-SK3 obtained using a prokaryotic expression system. The differential diagnostic test strip for HIV-1 antibodies was prepared by assembling the coated membrane with a non-woven fabric coated with protein A-coupled colloidal gold. The performance of the test strip was evaluated using samples of HIV-positive sera
HIV-negative sera
HIV serum panel
HIV Tiantan vaccine sera and other cross-reactive sera
and the test results using this strip were compared with those by ELISA.
Results
2
The sensitivity of SK1-SK2-SK3 coating on the novel differential diagnostic test strip for HIV-1 antibody detection was 93.5%
with a detection specificity of 100.0%. When combined with gp41 coating
the test strip showed a diagnostic sensitivity of 100.0%. The test results with the strip were consistent with those by ELISA (
P
>
0.05). For the Tiantan vaccine serum
the SK1-SK2-SK3 coating on the strip all yielded negative results without the false positive results of the gp41 coating.
Conclusion
2
This novel HIV-1 antibody diagnostic test strip can effectively distinguish the antibodies produced by HIV-1 infection from those generated by HIV-1 vaccination without false positive results as are common with the currently available commercial HIV test kits.
关键词
Keywords
references
VORONIN Y, ZINSZNER H, KARG C, et al. HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians[J]. Vaccine, 2015, 33(10): 1243-1249. DOI: 10.1016/j.vaccine.2014.10.040.
ACKERMAN M E, BAROUCH D H, ALTER G. Systems serology for evaluation of HIV vaccine trials[J]. Immunol Rev, 2017, 275(1): 262-270. DOI: 10.1111/imr.12503.
KHURANA S, NORRIS P J, BUSCH M P, et al. HIV-selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection[J]. J Clin Microbiol, 2010, 48(1): 281-285. DOI: 10.1128/JCM.01573-09.
KHURANA S, NEEDHAM J, PARK S, et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes[J]. J Acquir Immune Defic Syndr, 2006, 43(3): 304-312. DOI: 10.1097/01.qai.000024 2465.50947.5f.
KHURANA S, NEEDHAM J, MATHIESON B, et al. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies[J]. J Virol, 2006, 80(5): 2092-2099. DOI: 10.1128/JVI.80.5.2092-2099.2006.
YUAN Z W, SHUAI G Z, ZHANG J, et al. Expression of HIV trans-membrane protein gp41 and pronucleus gp36 and their antigenicity[J]. JThird Mil Med Univ, 2010, 32(21): 2281-2285.
YUAN Z W, CHEN W X, ZHANG J, et al. Development of an immunoassay for differentiating human immunodeficiency virus infections: from vaccine-induced immune response in Tiantan vaccine trials in China[J]. Clin Biochem, 2012, 45(15): 1219-1224.
YUAN Z W, ZHANG J, HU J L, et al. Prokaryotic expression and purification of HIV differential peptides for natural infection-elicited and vaccine-induced antibodies[J]. Chin J Biologicals, 2011, 24(11):1254-1258, 1263. DOI: 10.13200/j.cjb.2011.11.11.yuanzw.019.
GINN S L, AMAYA A K, ALEXANDER I E, et al. Gene therapy clinical trials worldwide to 2017: An update[J]. J Gene Med, 2018, 20(5): e3015. DOI: 10.1002/jgm.3015.
ACKERS M L, PAREKH B, EVANS T G, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients[J]. J Infect Dis, 2003, 187(6): 879-886. DOI: 10.1086/368169.
PITISUTTITHUM P, NITAYAPHAN S, THONGCHAROEN P, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults[J]. J Infect Dis, 2003, 188(2): 219-227. DOI: 10.1086/376506.
ALLEN M, ISRAEL H, RYBCZYK K, et al. Trial-related discrimination in HIV vaccine clinical trials[J]. AIDS Res Hum Retroviruses, 2001, 17(8): 667-674. DOI: 10.1089/088922201750236942.
ANDRABI R, BHIMAN J N, BURTON D R. Strategies for a multi-stage neutralizing antibody-based HIV vaccine[J]. Curr Opin Immunol, 2018, 53: 143-151. DOI: 10.1016/j.coi.2018.04.025.
KONG R, XU K, ZHOU T Q, et al. Fusion peptide of HIV-1as a site of vulnerability to neutralizing antibody[J]. Science, 2016, 352(6287): 828-833. DOI: 10.1126/science.aae0474.
LIAO H X, LYNCH R, ZHOU T Q, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus[J]. Nature, 2013, 496(7446): 469-476. DOI: 10.1038/nature12053.
DAVID D, GOOSSENS D, DESGRANGES C, et al. Molecular characterization of human monoclonal antibodies specific for several HIV proteins: analysis of the VH3 family expression[J]. Immunol Lett, 1995, 47(1/2):107-112.
ACKERS M L, PAREKH B, EVANS T G, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients[J]. J Infect Dis, 2003, 187(6): 879-886. DOI: 10.1086/368169.
ZHANG Q C, LIU Z, HOU J, et al. Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system[J]. Vaccine, 2016, 34(30): 3447-3453. DOI: 10.1016/j.vaccine.2016.05.012.
ZHANG Q C, TIAN M J, FENG Y, et al. Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain[J]. PLoS ONE, 2013, 8(4): e60557. DOI: 10.1371/journal.pone.0060557.
Current status and prospect for development of COVID-19 vaccine adjuvants
Advances in prevention and control for dengue fever
Prevention of vector-borne diseases and military medical support
Differential diagnosis of intestinal non-B cell lymphoma and Crohn's disease
Contrast-enhanced ultrasonography and time-intensity curve analysis for differential diagnosis of benign and malignant thyroid nodules
Related Author
Hao CHENG
Haibo LI
Jintao LI
Xiaofeng XU
Wenyue XU
Guangxian WANG
Chunliang LYU
Li YANG
Related Institution
Department of Microbiology and Biochemical Pharmacy, National Engineering Research Center of Immunological Products, Faculty of Pharmacy and Laboratory Medicine, Army Medical University (Third Military Medical University)
Department of Military Biosafety, College of Basic Medical Sciences, Army Medical University (Third Military Medical University)
Department of Pathogenic Biology, , College of Basic Medical Sciences, Army Medical University (Third Military Medical University)
Department of Medical Genetics, College of Basic Medical Sciences, Army Medical University (Third Military Medical University)
Department of Pathology, Second Affiliated Hospital, Army Medical University (Third Military Medical University)